Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 13/20 | 0.63 |
| ▸ | OPRK1 | P41145 | 7/20 | 0.63 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.63 |
| ▸ | APP | P05067 | 3/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.54 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.54 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22874143 | 0.88 | APP (0.56) | OPRD1OPRK1OPRM1APPMAPT | |
| SCHEMBL20004190 | 0.84 | HSD11B1 (0.60) | OPRD1OPRK1OPRM1APPMAPT | |
| SCHEMBL4916549 | 0.83 | OPRD1 (0.59) | OPRD1OPRK1OPRM1APPKCNH2 | |
| SCHEMBL20004189 | 0.82 | APP (0.54) | OPRD1OPRK1OPRM1APPMAPT | |
| SCHEMBL11159629 | 0.81 | APP (0.55) | OPRD1OPRK1OPRM1APPMAPT | |
| SCHEMBL3278422 | 0.81 | CA12 (0.56) | OPRD1OPRK1OPRM1APPMAPT | |
| SCHEMBL11624342 | 0.80 | APP (0.52) | OPRD1OPRK1OPRM1APPMAPT | |
| SCHEMBL1977504 | 0.79 | APP (0.54) | OPRD1OPRK1OPRM1APPMAPT | |
| SCHEMBL11264109 | 0.79 | OPRM1 (0.55) | OPRD1OPRK1OPRM1APPMAPT | |
| SCHEMBL2468057 | 0.79 | OPRD1 (0.50) | OPRD1OPRK1OPRM1APP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10889575-B2 | 4,4-diphenylpiperidine compounds or pharmaceutically acceptable salts thereof, pharmaceutical compositions and uses thereof | ACADEMY OF MILITARY MEDICAL SCIENCES (CN) | 2021-01-12 | — | — | US | disclosed |
| US-20190359604-A1 | 4,4-Diphenylpiperidine Compounds or Pharmaceutically Acceptable Salts Thereof, Pharmaceutical Compositions and Uses Thereof | ACADEMY OF MILITARY MEDICAL SCIENCES (CN) | 2019-11-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10889575-B2 | 4,4-diphenylpiperidine compounds or pharmaceutically acceptable salts thereof, pharmaceutical compositions and uses thereof | CACNA1B, CACNA1D, TRPV4 | OPRD1 37/4885OPRK1 62/4885OPRM1 110/4885 |
| US-20190359604-A1 | 4,4-Diphenylpiperidine Compounds or Pharmaceutically Acceptable Salts Thereof, Pharmaceutical Compositions and Uses Thereof | CACNA1B, CACNA1D, TRPV4 | OPRD1 39/4885OPRK1 61/4885OPRM1 115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.